Vimta Labs Limited
Quick Take
- • Trading at 33.8× trailing earnings
- • Strong ROE at 17.4%
- • Low leverage (D/E 0.01)
- • Modest dividend yield of 0.33%
- • Operating margin 22.7% · Net margin 18.9%
- • Profit growth +10.70% YoY · Beta -0.08
Latest quarter · Jun 2026
| ₹ Cr | Jun 2026 | QoQ | YoY |
|---|---|---|---|
| Revenue | 109 | +0.00% | +11.22% |
| Operating Profit | 41 | -2.38% | +17.14% |
| Net Profit | 21 | +0.00% | +10.53% |
| EPS (₹) | 4.66 | +0.87% | +10.69% |
Shareholding Pattern
| Dec 2024 | Mar 2025 | Jun 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Promoters▼0.18 | 36.76% | 36.70% | 36.67% | 36.67% | 35.99% | 35.90% | 35.85% | 35.67% |
| FIIs▼0.47 | 3.81% | 3.66% | 3.52% | 3.49% | 4.33% | 4.59% | 4.89% | 4.42% |
| DIIs▲0.23 | 1.16% | 1.43% | 1.42% | 1.42% | 0.87% | 0.11% | 0.14% | 0.37% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public▲0.43 | 58.27% | 58.20% | 58.39% | 58.42% | 58.80% | 59.41% | 59.12% | 59.55% |
| No. of Shareholders | 21,156 | 26,183 | 29,867 | 30,829 | 55,933 | 54,467 | 51,623 | 50,190 |
* The number of shareholders is based on unique PAN. Where a shareholder falls under more than one category, the shareholder has been counted only once under the category appearing first in the prescribed order, in accordance with the NSE FAQs on Shareholding Pattern, while the shareholding has been disclosed under the respective applicable categories.
| Date | Party | Type | Side | Qty | Price |
|---|---|---|---|---|---|
| 21 Jul 26 | Microcurves Trading Private Limited | Bulk deal | BUY | 3,66,347 | ₹603.90 |
| 21 Jul 26 | Microcurves Trading Private Limited | Bulk deal | SELL | 3,66,347 | ₹604.27 |
| 10 Mar 26 | Jagadeesh Kodali | Insider · - | Sell | 5,000 | ₹464.00 |
| 25 Sept 25 | Hrti Private Limited | Bulk deal | BUY | 2,95,059 | ₹753.57 |
| 25 Sept 25 | Hrti Private Limited | Bulk deal | SELL | 2,94,330 | ₹755.68 |
| 19 Sept 25 | Graviton Research Capital Llp | Bulk deal | BUY | 2,48,631 | ₹821.32 |
| 19 Sept 25 | Graviton Research Capital Llp | Bulk deal | SELL | 2,48,631 | ₹821.90 |
| 19 Sept 25 | Hrti Private Limited | Bulk deal | SELL | 3,93,620 | ₹822.81 |
| 19 Sept 25 | Hrti Private Limited | Bulk deal | BUY | 3,76,745 | ₹821.31 |
| 19 Sept 25 | Spdr Portfolio Emerging Markets Etf | Bulk deal | BUY | 3,46,373 | ₹824.05 |
About the company
From latest AR & concallVimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract research and testing for agrochemical and specialty chemical companies. It also provides food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters, and regulators; and a testing laboratory for water, alcoholic, and non-alcoholic beverages. In addition, the company offers environmental regulatory services, such as impact assessments and post project monitoring, to various industries, including power, infrastructure, cement, oil and gas, and mining, etc.; and EMI/EMC testing for electronic and electrical products/components. It provides solutions to agriculture, biologics and biosimilars, home and personal care, medical device, specialty chemicals, food, electrical and electronics, nutraceuticals, water and beverages, pharmaceuticals, crop care, environment, health and safety, and packaging industries. Vimta Labs Limited was founded in 1984 and is headquartered in Hyderabad, India.
